
    
      The investigation was a randomized, investigator-blinded, and parallel study, conducted in
      patients (age 1-15 years) with acute rhinosinusitis. Two groups of patients were randomized
      received low (10 MKD) or high (20 MKD) of drug for 14 days. Changes in sinus symptoms scores,
      response rate and adverse effect were evaluated at days 7 and 14. Relapse rate was recorded
      at days 21 and 28. Recurrence of sinus symptoms at day 60 were assessed.
    
  